Valuation: Healius Limited

Market Cap 309M 221M 190M 178M 163M 307M 21.1B 2.11B 817M 10.64B 830M 812M 35.25B P/E 2026
-0.68x
P/E 2027 * -29.5x
Enterprise Value 1.22B 872M 748M 702M 641M 1.21B 83.15B 8.31B 3.22B 41.95B 3.27B 3.2B 139B EV / Sales 2026
0.88x
EV / Sales 2027 * 0.88x
Free-Float
77.51%
Yield 2026 *
-
Yield 2027 * 2.93%
3 years 0.84
Extreme 0.84
0.97
5 years 0.84
Extreme 0.84
0.97
10 years 0.84
Extreme 0.84
2.7
Manager TitleAgeSince
Chief Executive Officer - 05/03/2024
Director of Finance/CFO - 13/10/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 21/08/2018
Chairman 65 28/11/2023
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-13.40%-.--% - - 221M
+0.58%+3.78%+103.59%+507.76% 48.53B
-0.51%+1.69%+20.68%+58.33% 27.39B
-1.86%-14.86%-15.86%-37.72% 7.23B
-0.43%+1.83%+9.00%+142.27% 6.05B
+1.23%+2.65%+17.11%+77.19% 3.35B
+3.41%+13.07%-28.67%+2,009.13% 2.61B
+3.48%+4.53%+159.85%+26.07% 2.16B
-1.45%+1.24%-7.80%-51.91% 2.02B
-0.48%+1.70%+31.38%+23.93% 1.97B
Average -0.94%+3.84%+32.14%+306.12% 11.26B
Weighted average by Cap. -0.03%+5.27%+58.32%+319.09%

Financials

2026 2027 *
Net sales 1.38B 988M 848M 796M 727M 1.37B 94.22B 9.42B 3.65B 47.53B 3.71B 3.63B 157B 1.41B 1.01B 870M 817M 746M 1.41B 96.68B 9.66B 3.75B 48.78B 3.81B 3.72B 162B
Net income -27.45M -19.67M -16.88M -15.85M -14.47M -27.31M -1.88B -188M -72.68M -947M -73.86M -72.25M -3.13B -10.8M -7.74M -6.64M -6.24M -5.7M -10.75M -738M -73.8M -28.6M -372M -29.07M -28.44M -1.23B
Net Debt 908M 651M 558M 524M 479M 903M 62.05B 6.2B 2.4B 31.3B 2.44B 2.39B 104B 934M 669M 574M 539M 492M 929M 63.82B 6.38B 2.47B 32.2B 2.51B 2.46B 107B
Logo Healius Limited
Healius Limited is a healthcare company. The Company's specialized pathology businesses deliver healthcare services across Australia. It provides pathology services, including specialty pathology and clinical trials. It offers medical laboratory and pathology services through a variety of specialty brands. It provides medical laboratory and pathology services across key diagnostic activities. These include anatomical pathology (histopathology and cytology), clinical pathology (biochemistry, hematology, immunology and microbiology), genomic diagnostics and veterinary pathology. Its brands include Abbot, Agilex Biolabs, Dorevitch, Gastrolab, Genomic Diagnostics, IQ Pathology, Kossard Dermatopathology, Laverty Pathology, QML Pathology, TML Pathology, Vetnostics Pathology and Western Diagnostic Pathology (WDP). These brands operate in Queensland, New South Wales (including the Australian Capital Territory), Victoria, Western Australia and Northern Territory, Tasmania, and South Australia.
Employees
6,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
0.4250AUD
Average target price
0.5474AUD
Spread / Average Target
+28.79%

Quarterly revenue - Rate of surprise